Beta-thalassemia intermedia
MONDO:0016487Beta-thalassemia (BT) intermedia is a form of BT characterized by mild to moderate anemia which does not or only occasionally requires transfusion.
34 clinical trials for this condition and its sub-types, 9 tagged with Beta-thalassemia intermedia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New study aims to boost growth and health in kids with thalassemia
Disease control OngoingThis study looks at growth problems in children with thalassemia, a blood disorder. Researchers will test a program that includes health education, nutrition plans, exercise, and support to help kids grow better. The goal is to improve height, weight, and overall well-being in 36…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill could boost red blood cells in thalassemia patients
Disease control OngoingThis phase 3 trial tests whether the drug mitapivat can improve anemia and reduce fatigue in people with alpha- or beta-thalassemia who do not need regular blood transfusions. About 194 participants received either mitapivat or a placebo daily for 24 weeks. The main goal is to se…
Phase 3 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug aims to tackle iron overload in thalassemia patients
Disease control OngoingThis Phase 2 trial tests an experimental drug called REGN7999 in about 95 people with non-transfusion dependent beta-thalassemia who have too much iron in their bodies. The drug is given as a shot under the skin and aims to safely reduce iron levels in the liver. Researchers will…
Phase 2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill shows promise for thalassemia patients in early trial
Disease control OngoingThis study tested a drug called AG-348 in 20 adults with a type of thalassemia that doesn't require regular blood transfusions. The goal was to see if the drug could safely raise hemoglobin levels, which carry oxygen in the blood. Participants took the pill twice a day for up to …
Phase 2 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC